View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 9, 2020

Study shows Nilvadipine slows early-stage Alzheimer’s disease

Roskamp Institute researchers have reported that the drug Nilvadipine demonstrated an ability to slow-down early-stage Alzheimer’s disease in a clinical study.

Roskamp Institute researchers have reported that the drug Nilvadipine demonstrated an ability to slow-down early-stage Alzheimer’s disease in a clinical study.

The data from the trial showed that early-stage Alzheimer’s patients who were taking Nilvadipine showed less cognitive decline over an 18-month period than patients treated with placebo.

The study also found that the use of language was better preserved after treatment with the drug in patients with mild Alzheimer’s, which is a slightly more advanced stage.

According to the institute, there was a 50% reduction in the rate of decline of the overall mental ability of very early-stage patients who were given Nilvadipine.

Headed by Dr Brian Lawlor at Trinity College Dublin, the new study was a follow up of data collected by Roskamp Institute scientists with a European network of collaborators in a study called NILVAD.

Roskamp Institute executive director Michael Mullan said: “Understanding how this drug may be beneficial in very early-stage patients is obviously important for further development of new treatments for Alzheimer’s disease.

“The development of drugs for Alzheimer’s Disease has been fraught with multiple late-stage clinical failures, but one area of consensus which has emerged is that for effectiveness of many experimental drugs the treatment must start very early in the disease process.”

Researchers found in another study that the drug can lower the levels of two toxic proteins in the brains of mice. The proteins, namely amyloid and tau, are said to develop Alzheimer pathology.

These findings are consistent with those in the human clinical trial.

In the study, the examination of cerebrospinal fluid samples from Alzheimer patients suggested that the improved mental functioning was associated with increased release of toxic amyloid out of the brain.

Nilvadipine was previously used to treat hypertension in Europe and Japan.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena